Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28110633 | 0.90 | CYP1A2 (0.37) | CYP1A2ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL18346643 | 0.84 | CYP1A2 (0.34) | CYP1A2ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL27794315 | 0.84 | TSHR (0.40) | CYP1A2ALDH1A1MAPTHTTTSHR | |
| SCHEMBL442643 | 0.80 | CYP1A2 (0.46) | CYP1A2ALDH1A1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL12172484 | 0.78 | TSHR (0.40) | CYP1A2TSHRSMN1; SMN2 | |
| SCHEMBL3688744 | 0.77 | CYP1A2 (0.56) | CYP1A2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9616911 | 0.75 | — | — | |
| SCHEMBL8226932 | 0.75 | — | — | |
| SCHEMBL28598751 | 0.75 | — | — | |
| SCHEMBL4072508 | 0.75 | CYP1A2 (0.65) | CYP1A2ALDH1A1L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513164-B | Transparent elastomer nanocomposite | 3M创新有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-112513196-B | Transparent elastomeric nanocomposite blends | 3M创新有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20170210994-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME, AND METHOD OF MANUFACTURING LIQUID CRYSTAL DISPLAY DEVICE | TCL CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) | 2017-07-27 | — | — | US | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-1753733-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | Avanir Pharmaceuticals (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123700-A1 | SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | AVANIR PHARMACEUTICALS | 2005-12-15 | — | — | US | disclosed |
| US-5631209-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5502027-A | ALGICIDES | ROHM AND HAAS COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0415642-B1 | Glutarimides | ROHM & HAAS (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5393735-A | N-(halo-oxy-)phenyl substituted cyclic imides | ROHM AND HAAS COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0415641-B1 | Substituted glutaramic acids and derivatives | ROHM & HAAS (US) | 1994-01-19 | — | — | EP | disclosed |
| US-5238908-A | HERBICIDAL GLUTARAMIC ACIDS AND DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0415641-A1 | Substituted glutaramic acids and derivatives | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415642-A1 | Glutarimides | ROHM AND HAAS COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | LDLR, NPC1L1, CETP | CYP1A2 2866/4885ALDH1A1 4484/4885LMNA 1880/4885 |
| US-20120053171-A1 | Nitrogen-Containing Fused Heterocyclic Compounds and Their use as Beta Amyloid Production Inhibitors | BACE1, APP, PSEN1 | CYP1A2 1313/4885ALDH1A1 3158/4885LMNA 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.